Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Akshay M Khatri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, UnityPoint Health-Des Moines, Des Moines, USA. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Isavuconazole (ISA) is a newer antifungal used in patients with history of hematologic malignancies and hematopoietic transplant and cellular therapies (HM/TCT). Although it has a more favorable side‐effect profile, breakthrough invasive fungal infections (bIFIs) while on ISA have been reported.
Methods
In this single‐center retrospective study evaluating HM/TCT patients who received prophylactic ISA for ≥7 days, we evaluated the incidence and potential risk factors for bIFIs.
Results
We evaluated 106 patients who received prophylactic ISA. The patients were predominantly male (60.4%) with median age of 65 (range: 21–91) years. Acute myeloid leukemia (48/106, 45.3%) was the most common HM, with majority having relapsed and/or refractory disease (43/106, 40.6%) or receiving ongoing therapy (38/106, 35.8%). Nineteen patients (17.9%) developed bIFIs–nine proven [ Fusarium (3), Candida (2), Mucorales plus Aspergillus (2), Mucorales (1), Colletotrichum (1)], four probable invasive pulmonary Aspergillus , and six possible infections. Twelve patients were neutropenic for a median of 28 (8–253) days prior to bIFI diagnosis. ISA levels checked within 7 days of bIFI diagnosis (median: 3.65 μg/mL) were comparable to industry‐sponsored clinical trials. All‐cause mortality among the bIFI cases was 47.4% (9/19).We also noted clinically significant cytomegalovirus co‐infection in 5.3% (1/19). On univariate analysis, there were no significant differences in baseline comorbidities and potential risk factors between the two groups.
Conclusion
ISA prophylaxis was associated with a significant cumulative incidence of bIFIs. Despite the appealing side‐effect and drug‐interaction profile of ISA, clinicians must be vigilant about the potential risk for bIFIs. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, UnityPoint Health-Des Moines, Des Moines, USA.
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, USA.
- Miami Transplant Institute, Jackson Health System, Miami, USA.
- Department of Pharmacy, Sylvester Comprehensive Cancer Center, Miami, USA.
- Department of Medicine, Division of Infectious Diseases, Mayo Clinic Health System-Eau Claire, Miami, USA.
- Division of Medical Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, USA.
ORCID-Profile: Akshay M Khatri, Yoichiro Natori, Anthony Anderson, Ra'ed Jabr, Jose F Camargo
Zitieren
APA
Khatri, A. M., Natori, Y., Anderson, A., Jabr, R., Shah, S. A., Natori, A., Chandhok, N. S., Komanduri, K., Morris, M. I., Camargo, J. F., & Raja, M. (2023). Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14162
Vancouver
Khatri AM, Natori Y, Anderson A, Jabr R, Shah SA, Natori A, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients. Transplant Infectious Disease. 2023. doi:10.1111/tid.14162
BibTeX
@article{Khatri2023,
author = {Khatri, Akshay M and Natori, Yoichiro and Anderson, Anthony and Jabr, Ra'ed and Shah, Shreya A and Natori, Akina and Chandhok, Namrata S and Komanduri, Krishna and Morris, Michele I and Camargo, Jose F and Raja, Mohammed},
title = {Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14162}
}
EUVIMED